Aug 21 (Reuters) - Krystal Biotech Inc KRYS.O:
KRYSTAL BIOTECH ANNOUNCES UPDATE ON DEVELOPMENT PLANS FOR ONCOLOGY PROGRAM KB707 AND PRIORITIZATION OF INHALED KB707 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KRYSTAL BIOTECH INC - GRANTED FDA MEETING FOR KB707 FOR OCTOBER
KRYSTAL BIOTECH INC - INHALED KB707 SAFE, NO GRADE 4 OR 5 ADVERSE EVENTS
KRYSTAL BIOTECH INC - PAUSES ENROLLMENT IN OPAL-1 STUDY
KRYSTAL BIOTECH INC - ENROLLMENT CONTINUES IN KYANITE-1 STUDY FOR INHALED KB707
KRYSTAL BIOTECH INC: CO MAY ADJUST DEVELOPMENT PLANS FOR INTRATUMORAL KB707